Business
Harrow Health to Announce Third Quarter 2020 Financial Results on November 9, 2020
NASHVILLE, Tenn., Oct. 27, 2020 (GLOBE NEWSWIRE) -- Harrow Health, Inc. (NASDAQ: HROW) today announced that after the close of trading on Monday, November 9,
About this update from Harrow, Inc.
[{"type":"text","content":"NASHVILLE, Tenn., Oct. 27, 2020 (GLOBE NEWSWIRE) -- Harrow Health, Inc. (NASDAQ: HROW) today announced that after the close of trading on Monday, November 9, 2020, it will release third quarter 2020 financial results and host a conference call at 4:45 p.m. Eastern Standard Time / 1:45 p.m. Pacific Standard Time to discuss the financial results and recent business developments.\n After the close of the market on November 9, 2020, Harrow will issue a press release containing a link to its third quarter 2020 Letter to Stockholders. The Letter to Stockholders will be archived on the Harrow Investor Relations website in the Archives section, along with the preceding letters, all of which can be found by clicking here. On the conference call, the primary objective is to allow analysts to engage in a question and answer session with the Harrow management team after providing a brief introduction, an overview of the quarter, and outlook for the business. Conference Call Details: U.S. callers: (844) 602-0380International callers: (862) 298-0970Audio-only webcast: please click here Conference Call Replay: A dial in replay of the call will be available until December 9, 2020. The webcast replay will be available until February 09, 2021. U.S. callers: (877) 481-4010, Replay ID: 38433International callers: (919) 882-2331, Replay ID: 38433Webcast: please click here About Harrow HealthHarrow Health, Inc. (NASDAQ: HROW) owns a portfolio of healthcare businesses, including ImprimisRx, the nation’s leading ophthalmology outsourcing facility and pharmaceutical compounding business. The company holds large equity positions in Eton Pharmaceuticals, Surface Pharmaceuticals, and Melt Pharmaceuticals. Harrow also owns Mayfield Pharmaceuticals, Stowe Pharmaceuticals, and Visionology, all companies founded as subsidiaries of Harrow Health. The Company also owns royalty rights in certain drug candidates being developed by Surface, Melt, and Mayfield. Harrow intends to create, invest in and grow paradigm shifting healthcare businesses that put patients first. For more information about Harrow Health, please visit the Investor Relations section of the corporate website by clicking here. Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any stateme...